- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Selicrelumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 2,338
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Nervous System Effects of Diphenhydramine, Pharmacokinetics of Diphenhydramine
- Interventions
- DiphenhydrAMINE Injectable Solution
- Drug
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-75098, BGB-43395, Fulvestrant
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more
- Conditions
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
- Interventions
- MLN3126, MLN3126 Matched Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Oncology
- Interventions
- BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
- Conditions
- Healthy Participants
- Interventions
- ASP8731, ASP8731 Matching Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Partial Obstruction of Systemic to Pulmonary Artery Shunt, Complete Obstruction of Systemic to Pulmonary Artery Shunt
- Interventions
- Cangrelor
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 1 Day to 28 Days
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- TAK-954, TAK-954 Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Cystic Fibrosis
- Interventions
- Ethambutol, Rifampin, Azithromycin, Pancrelipase
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 16 Years to 45 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cushing Syndrome
- Interventions
- LCI699
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- Bryostatin for Injection, Placebo
- Drug
- Lead sponsor
- Blanchette Rockefeller Neurosciences Insitute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- Concizumab, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 8
- States / cities
- Torrance, California • Indianapolis, Indiana • Iowa City, Iowa + 5 more
- Conditions
- Advanced Solid Tumor, DLBCL
- Interventions
- RNK05047
- Drug
- Lead sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • New York, New York
- Conditions
- Healthy
- Interventions
- PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, IPX054 300 mg
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Sunnyvale, California • Lawrence, Kansas
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- AMG 424
- Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- San Francisco, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 3 more
- Conditions
- Healthy
- Interventions
- Placebo (SC), LY3200327 (SC), LY3200327 (IV), Placebo (IV)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Adults
- Interventions
- BMS-986089, Placebo matching with BMS-986089
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Parkinson Disease
- Interventions
- DNL201, Placebo
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
- Interventions
- AVZO-103, Combination Agent
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Neoplasms, Melanoma
- Interventions
- Modakafusp Alfa, Pembrolizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide (GSK716155)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 30
- States / cities
- Dothan, Alabama • Long Beach, California • Riverside, California + 25 more
- Conditions
- Hereditary Angioedema
- Interventions
- STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin